Feng Xu1, Lingling Xu2, Qian Wang2, Guangyu An2, Guosheng Feng1, Fuquan Liu2. 1. Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University Beijing 100020, China. 2. Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University Beijing 100020, China.
Abstract
BACKGROUND: Recently, the association of immunological checkpoint marker programmed death ligand-1 (PD-L1) and the prognosis of various cancers has always been a research hotspot. The objective of this study is to assess the clinical value of PD-L1 as a novel prognostic biomarker of renal cell carcinoma (RCC). METHODS: Medline/PubMed, EMBASE, the Cochrane Library databases and Grey literature were searched up to 30 March 2015 for eligible studies of the association between PD-L1 expression and cancer-specific survival (CSS) in RCC. The risk ratio (RR) and its 95% confidence interval (CI) were calculated from the included studies. Moreover, the odds ratio (OR) was also extracted to evaluate the association between the clinicopathological parameters of participants and PDL1 expression. RESULTS: Five studies involving 1073 patients were included in the meta-analysis. The pooled results showed that positive/higher PD-L1 expression was a negative predictor for CSS with RR of 2.90 (95% CI: 1.64-5.13; Pheterogeneity. ≤ 0.001). Additionally, increased PD-L1 was found to be significantly associated with large tumor size (OR = 2.28, 95% CI: 1.61-3.23; Pheterogeneity. = 0.645), high TNM stage (OR = 4.37, 95% CI: 2.99-6.39; Pheterogeneity. = 0.676), poor nuclear grade (OR = 7.58, 95% CI: 5.26-10.92; Pheterogeneity. = 0.203) and present tumor necrosis (OR = 6.77, 95% CI: 4.73-9.71; Pheterogeneity. = 0.111) in renal cell carcinoma patients. CONCLUSION: The meta-analysis suggested that PD-L1 could act as a significant biomarker in the worse prognosis and adverse clinicopathologic features of renal cell carcinoma.
BACKGROUND: Recently, the association of immunological checkpoint marker programmed death ligand-1 (PD-L1) and the prognosis of various cancers has always been a research hotspot. The objective of this study is to assess the clinical value of PD-L1 as a novel prognostic biomarker of renal cell carcinoma (RCC). METHODS: Medline/PubMed, EMBASE, the Cochrane Library databases and Grey literature were searched up to 30 March 2015 for eligible studies of the association between PD-L1 expression and cancer-specific survival (CSS) in RCC. The risk ratio (RR) and its 95% confidence interval (CI) were calculated from the included studies. Moreover, the odds ratio (OR) was also extracted to evaluate the association between the clinicopathological parameters of participants and PDL1 expression. RESULTS: Five studies involving 1073 patients were included in the meta-analysis. The pooled results showed that positive/higher PD-L1 expression was a negative predictor for CSS with RR of 2.90 (95% CI: 1.64-5.13; Pheterogeneity. ≤ 0.001). Additionally, increased PD-L1 was found to be significantly associated with large tumor size (OR = 2.28, 95% CI: 1.61-3.23; Pheterogeneity. = 0.645), high TNM stage (OR = 4.37, 95% CI: 2.99-6.39; Pheterogeneity. = 0.676), poor nuclear grade (OR = 7.58, 95% CI: 5.26-10.92; Pheterogeneity. = 0.203) and present tumor necrosis (OR = 6.77, 95% CI: 4.73-9.71; Pheterogeneity. = 0.111) in renal cell carcinomapatients. CONCLUSION: The meta-analysis suggested that PD-L1 could act as a significant biomarker in the worse prognosis and adverse clinicopathologic features of renal cell carcinoma.
Authors: Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon Journal: Clin Cancer Res Date: 2011-02-25 Impact factor: 12.531
Authors: H Tamura; M Ishibashi; T Yamashita; S Tanosaki; N Okuyama; A Kondo; H Hyodo; E Shinya; H Takahashi; H Dong; K Tamada; L Chen; K Dan; K Ogata Journal: Leukemia Date: 2012-07-25 Impact factor: 11.528
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon Journal: Proc Natl Acad Sci U S A Date: 2004-11-29 Impact factor: 11.205
Authors: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: T K Choueiri; A P Fay; K P Gray; M Callea; T H Ho; L Albiges; J Bellmunt; J Song; I Carvo; M Lampron; M L Stanton; F S Hodi; D F McDermott; M B Atkins; G J Freeman; M S Hirsch; S Signoretti Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick Journal: Neuro Oncol Date: 2014-10-29 Impact factor: 12.300
Authors: H K Angell; J Lee; K-M Kim; K Kim; S-T Kim; S H Park; W K Kang; A Sharpe; J Ogden; A Davenport; D R Hodgson; J C Barrett; E Kilgour Journal: Oncoimmunology Date: 2018-12-10 Impact factor: 8.110
Authors: Franziska Erlmeier; Wilko Weichert; Andres Jan Schrader; Michael Autenrieth; Arndt Hartmann; Sandra Steffens; Philipp Ivanyi Journal: Med Oncol Date: 2017-04-21 Impact factor: 3.064
Authors: Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin Journal: Endocr Pathol Date: 2018-03 Impact factor: 3.943
Authors: M Abbas; S Steffens; M Bellut; H Eggers; A Großhennig; J U Becker; G Wegener; A J Schrader; V Grünwald; P Ivanyi Journal: Med Oncol Date: 2016-06-17 Impact factor: 3.064
Authors: Min Hye Kim; Gyung Hyuk Ko; Jeong Hee Lee; Jong Sil Lee; Dong Chul Kim; Jung Wook Yang; Hyo Jung An; Ji Min Na; Dae Hyun Song Journal: In Vivo Date: 2021 May-Jun Impact factor: 2.155